Novartis gains European approval for ranibizumab

Article

Novartis will be the first company to offer licensed therapy ranibizumab to treat myopic choroidal neovascularisation (CNV).

Novartis will be the first company to offer licensed therapy ranibizumab to treat myopic choroidal neovascularisation (CNV).

Approval was granted after data from the Novartis-sponsored clinical trial RADIANCE. The study demonstrated that ranibizumab provides superior improvement in visual acuity compared to current treatment methods such as verteporfin PDT.

CND patients will receive one ranibizumab injection and further injections based on individual requirements. Monitoring is needed for at least two months, with retreatment administered based on vision and anatomical changes.

Mr Adnan Tufail, consultant ophthalmologist at Moorfields Eye Hospital, London, UK, said, “The use of Lucentis in the treatment of myopic CNV will significantly change how this condition is treated. Until now, this has been an area where there is high unmet medical need. At best we have only been able to stabilise vision and prevent further vision loss in people with myopic CNV with current licensed treatments.

“Lucentis is the first anti-VEGF therapy licensed for this condition and, as the clinical trials have shown, it can restore vision rapidly in some patients with just a few injections.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.